| Molecular formula | C194H312N54O59S2 |
|---|
| Molecular weight | 4409 g/mol |
|---|
| Registered trials | 46 |
|---|
| PubChem CID | 171397054 |
|---|
Cagrilintide is an investigational peptide that has not received FDA approval and carries no approved drug label. People researching it often want to know what it actually is and how much clinical testing has been done.
What cagrilintide is
Cagrilintide is a long acting amylin analogue, a peptide compound identified by PubChem CID 171397054. It is studied as part of combination research, including the investigational agent CagriSema, but it does not have an FDA-approved label, indication, or prescribing information at this time.
Trial footprint
Cagrilintide has been studied across 46 registered clinical trials. A completed phase 3 trial compared CagriSema to tirzepatide for weight loss in people with obesity. Other ongoing studies include a phase 3 trial evaluating blood sugar and body weight effects of CagriSema in children and adolescents with type 2 diabetes, and a phase 1 trial examining the role of cagrilintide in bone metabolism.
FAQ
No. Cagrilintide is an investigational compound and does not have an FDA-approved label or indication. It is currently studied only in research settings, including clinical trials.
Cagrilintide is a long acting amylin analogue, a type of peptide. It is identified in chemical databases by PubChem CID 171397054.
Cagrilintide has been registered in 46 clinical trials. These include studies of the investigational combination CagriSema as well as trials looking at cagrilintide on its own, such as research into bone metabolism.
CagriSema is an investigational combination that includes cagrilintide, studied in trials comparing it to other therapies for weight loss and blood sugar control. Like cagrilintide alone, it does not have FDA approval.
No FAERS adverse event data is currently available for cagrilintide, since it is not an approved product with a marketed label.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-11-07